Qiagen to Gain Array-Based Breast Cancer Test through Ipsogen Buy | GenomeWeb

By Justin Petrone

Qiagen's planned acquisition of Ipsogen will provide the firm not only with a suite of CE-IVD marked PCR tests but an Affymetrix-manufactured microarray test that can be used to guide treatment for breast cancer patients.

Qiagen last week announced its intent to acquire molecular diagnostics firm Ipsogen for €70 million ($101 million). Qiagen is headquartered in Venlo, The Netherlands. Ipsogen is based in Marseille, France.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.